Live Breaking News & Updates on ப்ரூஃப் வாழும்|Page 5

Stay updated with breaking news from ப்ரூஃப் வாழும். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Trudeau's science adviser preparing report on COVID-19 vaccine passports


Trudeau’s science adviser preparing report on COVID-19 vaccine passports
Bookmark
Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file .
This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
People in a Tel Aviv audience wear protective face masks during a performance by Israeli musician Ivri Lider at a soccer stadium on March. 5, 2021. All guests were required to show a Green Pass for proof of COVID-19 vaccination or full recovery from the virus, a tool Canadian authorities are also considering.
Oded Balilty/The Associated Press ....

Patty Hajdu , Justin Trudeau , Peter Loewen , Jagmeet Singh , Mona Nemer , Oded Balilty , European Union , Public Policy Forum , Associated Press , Minister Justin Trudeau , Chief Science Adviser Mona Nemer , Green Pass , Digital Green Pass , Health Minister Patty Hajdu , Rempel Garner , Vaccine Passports , Green Passport Israel , Canada Vaccines , Covid 19 Vaccines , Covid 19 Vaccine Passport , Proof Of Vaccination , Chief Science Advisor , ஜஸ்டின் திருடேௌஉ , பீட்டர் லோவன் , ஜாக்மீட் சிங் , மோனா நேமேற் ,

ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV


(1)
The phase IIa proof-of-concept findings from ViiV Healthcare s innovative early pipeline of medicines show the antiviral activity, safety and tolerability of GSK 254 and support its continued study in phase IIb
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive data from its phase IIa proof-of-concept study of the investigational maturation inhibitor GSK3640254 (GSK 254). The study showed the antiviral activity of GSK 254, establishing a relationship between dose and antiviral response, with the 140 mg and 200 mg doses showing the greatest reduction in plasma HIV-1 RNA. These findings were presented today at the (virtual) 2021 Conference on Retroviruses and Opportunistic Infections (CROI). ....

North Carolina , United States , City Of , United Kingdom , Kimberly Smith , Kathleen Quinn , Jeff Mclaughlin , Simon Steel , Sonya Ghobrial , Audrey Abernathy , Kostenloser Wertpapierhandel , James Dodwell , Tim Foley , Kristen Neese , Melinda Stubbee , Company Form , Department Of Internal Medicine , Technical University Of Munich , Company Annual , Pfizer Inc , Head Of Research Development At Viiv Healthcare , Viiv Healthcare , Shionogi Limited , Opportunistic Infections , Research Development , Internal Medicine ,

No proof of life yet of Dubai princess: UN


Sheikha Latifa bint Mohammed Al Maktoum speaking into a mobile phone camera. Picture credit (AP)
GENEVA: The United Nations said on Friday it was yet to see evidence from the United Arab Emirates government that Dubai s Sheikha Latifa was still alive.
The UN rights office had asked to see proof that the daughter of Dubai ruler Sheikh Mohammed bin Rashid Al-Maktoum was still alive, but when asked if it had been received, spokesman Rupert Colville told reporters: Not yet, no.
FacebookTwitterLinkedinEMail ....

United Arab Emirates , Rupert Colville , Sheikha Latifa , Rashid Al Maktoum , United Nations , Sheikh Mohammed , Dubai Princess , ஒன்றுபட்டது அரபு அமீரகங்கள் , ரூபர்ட் கொல்வில்லி , ஷேக்கா லதிபா , ரஷித் அல் மெக்டூம் , ஒன்றுபட்டது நாடுகள் , ஷேக் முகமது , துபாய் ப்ரிந்ஸெஸ் ,